<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2025.1662312</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of exosome miRNAs regulated by SPHK2 in human glioma cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Jing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3127899/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Huafu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2160327/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Xia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Guan</surname><given-names>Xiaoyun</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Guo</surname><given-names>Qiyu</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xu</surname><given-names>Yanwen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Qiu</surname><given-names>Jinhua</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Departments of Pathology and Translational Medicine Institute, Shenzhen Second People&#x2019;s Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center</institution>, <city>Shenzhen</city>, <state>Guangdong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Neurology, Huizhou First Hospital</institution>, <city>Huizhou</city>, <state>Guangdong</state>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Jinhua Qiu, <email xlink:href="mailto:laoqjh@163.com">laoqjh@163.com</email>; Yanwen Xu, <email xlink:href="mailto:xyw0905@email.szu.edu.cn">xyw0905@email.szu.edu.cn</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-12-16">
<day>16</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1662312</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>11</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Liu, Zhao, Liu, Guan, Guo, Xu and Qiu.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Liu, Zhao, Liu, Guan, Guo, Xu and Qiu</copyright-holder>
<license>
<ali:license_ref start_date="2025-12-16">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Glioma is the most common primary brain tumor, and the WHO 4 glioma, glioblastoma (GB), is a malignant tumor with high invasiveness and mortality. Tumor-associated macrophages (TAMs), as the main immune cells in glioma, play an important role in the growth, invasiveness, immune escape, and drug resistance. The M2 phenotype of macrophages, but not the M1 phenotype, promotes glioma development. Recent studies have shown that sphingosine kinase 2 (SPHK2) is positively associated with TAM infiltration and glioma proliferation. SPHK2-deficient tumors showed impaired growth and failed to polarize macrophages toward an M2 phenotype.</p>
</sec>
<sec>
<title>Objective</title>
<p>Our aim was to reveal whether SPHK2 affects exosome microRNA (miRNA) release from glioma cells and which miRNAs regulated by SPHK2 could mediate the polarization of macrophages around glioma cells.</p>
</sec>
<sec>
<title>Methods</title>
<p>SPHK2 knockdown of the human glioma cell line U373 was performed using short hairpin RNA (shRNA) lentiviruses. Exosome miRNAs were isolated and evaluated using RNA sequencing (RNA-seq). Gene Ontology (GO) analysis was carried out to determine the function of exosome miRNAs targeting genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to view the pathways of these genes.</p>
</sec>
<sec>
<title>Results</title>
<p>We successfully isolated exosomes from the U373-HK and U373-SH glioma cell lines. We found 12 exosome miRNAs differentially expressed between U373-HK and U373-SH cells. The heatmap showed two upregulated and 10 downregulated miRNAs in glioma cells with SPHK2 knockdown. There were 12 miRNAs targeting genes assigned to 118 GO terms, including 53 biological processes, 30 cellular components, and 35 molecular function terms. KEGG mapping further clustered several signaling pathways, such as &#x201c;Wnt signaling,&#x201d; &#x201c;p53 signaling,&#x201d; &#x201c;proteoglycans in cancer,&#x201d; and &#x201c;cell cycle.&#x201d; &#x201c;Wnt signaling&#x201d; was identified as the most significantly enriched pathway in the KEGG analysis. A total of 17 genes were enriched in this pathway.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>The present study elucidates that SPHK2 promoted the release of 10 exosome miRNAs, but inhibited the release of two miRNAs. The KEGG data indicated that these miRNAs targeted several important genes of Wnt signaling. This study provides not only a genomic resource for further studies but also novel insights into uncovering the molecular mechanism of SPHK2 regulating M2 TAM polarization.</p>
</sec>
</abstract>
<kwd-group>
<kwd>glioma</kwd>
<kwd>macrophage</kwd>
<kwd>sphingosine kinase 2</kwd>
<kwd>exosome</kwd>
<kwd>miRNA</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Science, Technology and Innovation Commission of Shenzhen Municipality</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100010877</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">JCYJ20230807115108018, JCYJ20220530151209021</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">
<institution-wrap>
<institution>Sanming Project of Medicine in Shenzen Municipality</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100012151</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp2">SZSM202411003</award-id>
</award-group>
<funding-statement>The author(s) declared that financial support was received for&#xa0;this work and/or its publication. This project was supported by the Shenzhen Science and Technology Innovation Commission and Sanming Project of Medicine in Shenzhen (no. JCYJ20230807115108018, no. JCYJ20220530151209021, No. SZSM202411003).</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="30"/>
<page-count count="9"/>
<word-count count="3337"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuro-Oncology and Neurosurgical Oncology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Glioma is the most common primary brain tumor, and the WHO&#xa0;4 grade glioma, glioblastoma (GB), is a malignant tumor with high invasiveness and mortality (<xref ref-type="bibr" rid="B1">1</xref>). GB has characteristics of special location, infiltrative growth, difficult operation, and poor efficiency of chemoradiotherapy, with the median survival of the majority of patients being less than 1 year after administration of multimodal therapies (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). For many years, studies on the characteristics and the&#xa0;molecular mechanisms of the occurrence, progression, and prognosis of malignant glioma have progressed, but there is no breakthrough in the treatment of glioma. In recent years, studies have increasingly shown that tumor resistance to treatment is not necessarily an internal problem, and the interaction between glioma and the tumor microenvironment also makes the disease resistant to&#xa0;drugs (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). It is known that, in the course of tumor development,&#xa0;a&#xa0;large number of&#xa0;immune cells congregate in the tumor, the majority of which are&#xa0;tumor-associated macrophages (TAMs). Eventually, the majority of these are activated to anti-inflammatory macrophages (M2&#xa0;macrophages), but not pro-inflammatory macrophages (M1 macrophages), for the construction of a supportive microenvironment to promote tumor growth (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Recent studies have shown that sphingosine kinase 2 (SPHK2) plays a role in the phenotypes and function alterations of TAMs (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). TAMs from SPHK2-deficient tumors display a pronounced antitumor phenotype, showing an increased expression of pro-inflammatory markers/mediators such as nitric oxide (NO), tumor necrosis factor alpha (TNF-&#x3b1;), interleukin 12 (IL-12), and major histocompatibility complex II (MHCII) and a low expression of the anti-inflammatory IL-10 and CD206 (<xref ref-type="bibr" rid="B9">9</xref>). Our previous study found that the expression level of SPHK2, the macrophage marker CD68, and the M2-type TAM (anti-inflammatory tumor-promoting) markers in glioma tissues were higher than those in the control brain tissue (<xref ref-type="bibr" rid="B10">10</xref>). We also verified that miR-137 is a diagnostic tumor-suppressive microRNA (miRNA) that targets SPHK2 to promote M1-type TAM polarization, which successfully established glioma cell lines with SPHK2 knockdown using the lentiviral infection method (<xref ref-type="bibr" rid="B11">11</xref>). These studies indicate that SPHK2 could regulate the phenotype polarization of TAMs; however, the mechanism has not been elucidated.</p>
<p>In recent years, research on the exosome in tumors has been increasing, and more and more studies have shown that the exosome derived from tumor cells can promote tumor growth (<xref ref-type="bibr" rid="B12">12</xref>). With the exosome as a carrier of &#x201c;cancer seed&#x201d; dissemination, its secretion can be used as a clinical diagnostic marker and plays a crucial role in the maturation and secretion of intracellular composition (<xref ref-type="bibr" rid="B12">12</xref>). The exosome has an effect on the intercellular material and on information transduction, which can affect tumor growth through antitumor immunity, inhibition of immune function, and mediating tumor immune escape (<xref ref-type="bibr" rid="B13">13</xref>). Recent research has shown that SPHK2 mediating the S1P signaling pathway activates the maturation of secretion, molecular loading, and secretion, which is important in many biological functions of glioma (<xref ref-type="bibr" rid="B14">14</xref>), suggesting that SPHK2 may affect macrophage polarization through exosome release and function.</p>
<p>Exosomes contain DNAs, proteins, messenger RNAs (mRNA), miRNAs, and many other substances. Among these, miRNAs are the most widely studied substances. Numerous studies have shown that the development of a tumor is often accompanied by the abnormal secretory events of the exosome and exosome miRNAs (<xref ref-type="bibr" rid="B15">15</xref>). It is possible to identify an abnormal event in a certain tumor, and it is possible to obtain reliable diagnostic markers and therapeutic targets (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>At present, the research on the role of the exosome or exosome miRNA secretion in malignant glioma and its effect on the microenvironment of tumors is still in its infancy.</p>
<p>Based on the literature and our previous research, in this study, we demonstrate whether and which exosome miRNAs SPHK2 regulates in glioma cells. This article will display the exosome miRNAs possibly associated with the mechanism of TAM polarization mediated by SPHK2 and will aid in exploring the interaction between glioma and the microenvironment, the formation mechanism of the microenvironment, and useful targets and strategies for glioma treatment.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Cell lines and cell culture</title>
<p>The human glioma cell lines U251 and U373 and normal human astrocyte (HA) were purchased from China Academia Sinica Cell Repository (Shanghai, China). The cells were cultured in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS; Gibco) at 37&#xb0;C with 5% CO<sub>2</sub>.</p>
</sec>
<sec id="s2_2">
<title>Exosome isolation from cells</title>
<p>Approximately 2 &#xd7; 10<sup>6</sup> of the glioma cell lines U373 and U251 were seeded in 10 ml DMEM supplemented with 10% no-exosome FBS. After 48 h, the exosomes were isolated from the cell medium using the RiboTM Exosome Isolation Reagent (Ribobio, Shanghai, China).</p>
</sec>
<sec id="s2_3">
<title>Nanoparticle tracking analysis</title>
<p>Nanoparticle tracking analysis (NTA) measurements were performed using NTA with ZetaView PMX110 (Particle Metrix, Meerbusch, Germany) and the corresponding software ZetaView. The samples were processed in duplicate and diluted using 1&#xd7; phosphate-buffered saline (PBS) buffer before analysis. The detailed operation procedure was carried out according to the instruction manual.</p>
</sec>
<sec id="s2_4">
<title>Electron microscopy</title>
<p>The exosomes were isolated from the cell medium using the RiboTM Exosome Isolation Reagent (Ribobio, Shanghai, China). The exosome suspension was fixed with paraformaldehyde. Thereafter, 5 &#x3bc;l of the suspended droplets was fixed with a copper net and placed at room temperature for 20 min. Tweezers were used to hold the copper net and for rinsing in the PBS drops. Subsequently, 50 &#x3bc;l of 1% glutaraldehyde was added to the copper&#xa0;net and fixed for 5 min. The copper net was then rinsed with deionized water, 50 &#x3bc;l of uranium acetate was added, and fixed&#xa0;for 5&#xa0;min. A 50-&#x3bc;l mixture of uranyl acetate and methylcellulose was added on the copper net and fixed on ice for 10 min. A filter paper&#xa0;was used to remove the floating liquid and dried at room temperature for 5&#x2013;10 min. Images were recorded on a transmission electron microscope (TEM) (JEM-1200EX, Jeol, Tokyo, Japan).</p>
</sec>
<sec id="s2_5">
<title>Lentivirus and stable sub-cell line construction</title>
<p>Empty vector lentiviruses (vector) and lentiviruses expressing SPHK2 short hairpin RNAs (shRNAs) (SPHK2-SH1, SPHK2-SH2, and SPHK2-SH3) with puromycin resistance were constructed and packed by Hanbio (Shanghai, China). The titers of the viral solutions were 1.0&#x2013;1.2 &#xd7; 10<sup>9</sup>/ml. U373 and U251 cells were infected with 50 &#x3bc;l of the lentivirus solution per 6-cm dish. At 48 h after infection, the cells were treated with 8 &#x3bc;g/ml puromycin for 14 days for the selection of stable sub-cell lines (vector, SPHK2-SH1, SPHK2-SH2, and SPHK2-SH3).</p>
</sec>
<sec id="s2_6">
<title>Exosome RNA isolation, cDNA library construction, and RNA sequencing</title>
<p>Total RNA was used for the construction of a small RNA (sRNA) library. Briefly, the 3&#x2032; and 5&#x2032; RNA adapters were ligated to the RNA molecules, followed by reverse transcription to synthesize the first-strand complementary DNA (cDNA). The resulting cDNA was then amplified by PCR. The final cDNA libraries, enriched with inserts of approximately 18&#x2013;40 nucleotides (nt), were selected by size using gel electrophoresis and quantified. Sequencing was performed on an Illumina HiSeq 2500 platform to generate 50-nt single-end raw reads. For data processing, the raw reads were initially processed to remove adapter sequences and low-quality reads (e.g., those with ambiguous bases or low-quality scores). The resulting clean reads were used for subsequent analysis. The length distribution of these clean reads and the common sequences shared between samples were analyzed. These clean reads were then aligned and annotated against reference databases (e.g., miRBase and Rfam) to identify known RNA species (such as miRNAs and piRNAs, among others) and to quantify their expression. Finally, the unannotated reads were subjected to novel miRNA prediction using tools such as miRDeep2.</p>
</sec>
<sec id="s2_7">
<title>Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway mapping analyses</title>
<p>The target genes of the differentially expressed miRNAs were predicted using a combination of two databases, TargetScan and miRDB, to enhance prediction reliability. The genes identified by both algorithms were considered high-confidence targets for subsequent functional analysis. Functional annotation of these target genes was performed using the DAVID Bioinformatics Resource. Gene Ontology (GO) enrichment analysis was conducted to identify the significantly overrepresented terms in the biological process and cellular component domains, with a significance threshold of <italic>p</italic> &lt; 0.05. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was employed to delineate the key biochemical and signal transduction pathways the target genes are involved in using a more stringent threshold of <italic>p</italic> &lt; 0.01.</p>
</sec>
<sec id="s2_8">
<title>Statistical analyses</title>
<p>Normality of the distributions was estimated using the Kolmogorov&#x2013;Smirnov test. Differences among/between sample groups were analyzed using one-way ANOVA or Student&#x2019;s <italic>t</italic>-test with SPSS 18.0 software. Data are presented as the mean &#xb1; standard deviation (SD). Statistical significance was assigned at *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, or ***<italic>p</italic> &lt; 0.001. All the experiments of the cell lines were performed at least three times with triplicate samples.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Characterization of isolated exosomes</title>
<p>Exosomes were successfully isolated from the cell medium of HA, U373, and U251. These were examined using NTA (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1A, B</bold></xref>). The results showed that the exosomes from the U373 cell medium had a mean particle diameter of 113.3 &#xb1; 49.8 nm, while that of the exosomes from the U251 cell exosome sample was 120.1 &#xb1; 58.8 nm. The exosomes isolated from the U251 supernatant were visualized by TEM as nanovesicles ranging in size from 50 to 150 nm (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Characterization of the isolated exosomes. <bold>(A, B)</bold> Exosomes from the medium of the glioma cell lines U373 and U251 examined using nanoparticle tracking analysis. <bold>(C)</bold> Exosomes isolated from the U251 supernatant visualized by TEM.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1662312-g001.tif">
<alt-text content-type="machine-generated">Graphs and images displaying data on U373 and U251 exosomes. Chart A shows a peak concentration of U373 exosomes around 113.3 nm, while chart B shows U251 exosomes peaking at 120.1 nm. Below, image C shows a microscopic view of exosomes with a magnified section highlighting their structure.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_2">
<title>Identification of differentially expressed exosome miRNAs between U373-HK and U373-SH cells</title>
<p>We have previously published the verification of SPHK2 knockdown in our earlier article (<xref ref-type="bibr" rid="B11">11</xref>). The exosome sRNA was isolated and the gene expression profiles analyzed to identify the differentially expressed miRNAs between U373-HK and U373-SH cells. We found 12 exosome miRNAs differentially expressed between U373-HK and U373-SH cells. The heatmap showed that miRNA-4454 and miRNA-4516 were upregulated in glioma cells with SPHK2 knockdown, while miRNA-195-5p, miRNA-1273d, miRNA-3158-3p, miRNA-3689a-5p, miRNA-3689b-5p, miRNA-3689e, miRNA-548aa, miRNA-548t-3p, miRNA-548-5p, and miRNA-387e were downregulated in glioma cells with SPHK2 knockdown (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>). We speculate that the expression and the transportation of these exosome miRNAs were affected by SPHK2 and that these miRNAs could mediate macrophage polarization through exosomes entering macrophages.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Identification of differential exosome miRNAs between U373-HK and U373-SH cells. Differential miRNAs were visualized, with the scale from the least abundant to the highest range being from &#x2212;1.5 to 1.5. Their phylogenetic relationships are shown on the <italic>left tree</italic>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1662312-g002.tif">
<alt-text content-type="machine-generated">Heatmap showing expression levels of various microRNAs across different samples. Rows represent microRNAs such as hsa-miR-4454, while columns represent samples like U373-HK1. Red indicates higher expression, green lower, with a gradient scale from -1.5 to 1.5.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_3">
<title>GO classifications</title>
<p>GO is a universally acknowledged gene functional enrichment database and is generally applied to determine enriched GO terms (<xref ref-type="bibr" rid="B17">17</xref>). Therefore, GO analysis was performed using hypergeometric distribution to obtain the most significant function of a series of genes (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). A total of 12 miRNAs were assigned to 118 GO terms, including 53 biological processes, 30 cellular components, and 35 molecular function terms. Typical enriched GO terms are shown in <xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>. The GO terms of the molecular function category were concentrated in &#x201c;protein binding&#x201d; (414 genes, 54.83%). The highest percentages of GO terms under the cellular component class were &#x201c;nucleus&#x201d; (261 genes, 34.57%) and &#x201c;cytoplasm&#x201d; (254 genes, 33.64%). The most prevalent &#x201c;biological process&#x201d; assignment was &#x201c;transcription, DNA-templated,&#x201d; including 106 genes and accounting for 14.04% of all genes. Moreover, other important assignments, such as &#x201c;regulation of transcription, DNA-templated&#x201d; (84 genes, 11.13%) and &#x201c;positive regulation of transcription from RNA polymerase II promoter&#x201d; (57 genes, 7.55%), were highly enriched, suggesting that glioma cells could alter the transcription of other cells around them through exosome miRNAs.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Gene Ontology (GO) functional classification of the miRNA targeting genes. The distributions are summarized into three main categories: biological process, molecular function (MF), and cellular component (CC). The <italic>x</italic>-axis indicates the different GO terms, while the <italic>y</italic>-axis indicates the number of genes in each category.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1662312-g003.tif">
<alt-text content-type="machine-generated">Bar chart displaying the number of target genes associated with different biological processes, cellular components, and molecular functions. The biological processes are shown in green, cellular components in blue, and molecular functions in purple. The y-axis indicates the number of target genes, ranging from zero to four hundred. Each bar is labeled with its corresponding Gene Ontology (GO) description.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_4">
<title>The &#x201c;Wnt signaling pathway&#x201d; was significantly enriched by KEGG mapping</title>
<p>The KEGG database is a collection of various pathways representing the molecular interactions and reaction networks (<xref ref-type="bibr" rid="B20">20</xref>). To identify the downstream signaling pathways regulated by the identified exosome miRNAs, we mapped the KEGG database and found that the identified genes were significantly enriched in nine KEGG pathways, as shown in <xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>. The genes were highly clustered in several signaling pathways, such as &#x201c;Wnt signaling,&#x201d; &#x201c;p53 signaling,&#x201d; &#x201c;proteoglycans in cancer,&#x201d; and &#x201c;cell cycle,&#x201d; suggesting that exosome miRNAs may perform their function through these pathways. &#x201c;Wnt signaling&#x201d; was identified as the most significantly enriched pathway in the KEGG analysis (gene ratio = 17/292, <italic>p</italic> &lt; 0.001). A total of 17 genes were enriched in this pathway (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref>). Moreover, 15 genes (i.e., <italic>SKP1</italic>, <italic>GSK3B</italic>, <italic>LRP6</italic>, <italic>BTRC</italic>, <italic>CCN4</italic>, <italic>INVS</italic>, <italic>SMAD4</italic>, <italic>SFRP1</italic>, <italic>NLK</italic>, <italic>FZD1</italic>, <italic>FZD2</italic>, <italic>FZD7</italic>, <italic>PRKACB</italic>, <italic>AXIN2</italic>, and <italic>PRICKLE2</italic>) were upregulated and two genes (i.e., <italic>TBL1XR1</italic> and <italic>TP53</italic>) were downregulated (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Bar chart of the results of the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The <italic>color</italic> and the <italic>size of the dots</italic> represent the range of the <italic>p</italic>-values and the number of genes mapped to the indicated pathways, respectively. All 12 miRNAs targeting genes in the enriched pathways are shown.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1662312-g004.tif">
<alt-text content-type="machine-generated">Horizontal bar chart showing various biological terms including &#x201c;Wnt signaling pathway,&#x201d; &#x201c;p53 signaling pathway,&#x201d; and &#x201c;Cellular senescence&#x201d; on the y-axis and their corresponding counts on the x-axis. Bars are colored based on p-values, indicated by a gradient from red to blue, with red representing lower p-values (5e-04) and blue representing higher (1e-03).</alt-text>
</graphic></fig>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Gene expression profile of the &#x201c;Wnt pathway.&#x201d; The map of the &#x201c;Wnt pathway&#x201d; was modified from the Kyoto Encyclopedia of Genes and Genomes (KEGG) map. The <italic>red boxes</italic> indicate the upregulated genes, while the <italic>green boxes</italic> indicate the downregulated genes identified by KEGG mapping.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1662312-g005.tif">
<alt-text content-type="machine-generated">Diagram of the WNT signaling pathway including canonical, planar cell polarity (PCP), and Wnt/Ca&#xb2;&#x207a; pathways. Highlighted components include FRP, GSK-3&#x3b2;, NFAT, and others. Connections indicate signaling interactions and processes such as gene transcription, phosphorylation, and ubiquitin-mediated proteolysis. A color scale represents activity levels. Rendered by Pathview.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Building on previous findings, this study aimed to determine whether SPHK2 regulates the release of exosomal miRNAs from glioma cells and to identify specific miRNAs that could potentially participate in macrophage polarization. The foundation for this inquiry includes reports that SPHK2 knockdown suppresses GB proliferation (<xref ref-type="bibr" rid="B21">21</xref>) and our own observation linking SPHK2 to TAM infiltration and glioma progression (<xref ref-type="bibr" rid="B10">10</xref>). While we have shown that miR-137 can drive M1 polarization by targeting SPHK2 (<xref ref-type="bibr" rid="B16">16</xref>), other studies have indicated a broader role, as SPHK2-deficient xenografts fail to polarize macrophages toward an anti-inflammatory phenotype and to exhibit a stunted growth (<xref ref-type="bibr" rid="B9">9</xref>). Therefore, the collective evidence positions SPHK2 as a key regulator of glioma growth through its influence on the polarization of TAMs.</p>
<p>Exosomes have emerged as key vehicles for intercellular communication, executing their pleiotropic functions through the targeted delivery of diverse cargo, including multiple RNA classes (both coding and non-coding), proteins, and lipids (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>). In oncology, a critical manifestation of this process is the dynamic cross-talk between malignant cells and TAMs, which facilitates tumor progression and invasion while simultaneously offering novel avenues for therapeutic interventions (<xref ref-type="bibr" rid="B25">25</xref>). Supporting the functional relevance of exosomal cargo, the contents of Panc-1 cell-derived exosomes have been demonstrated to promote the polarization of J774.A1 macrophages toward an M1 phenotype (<xref ref-type="bibr" rid="B26">26</xref>). In light of these observations, we hypothesize that a key mechanism through which SPHK2 regulates TAM polarization is via the specific modulation of the exosomal miRNA cargo.</p>
<p>Our analysis revealed that SPHK2 knockdown altered the expression of 12 exosomal miRNAs in glioma cells. The 1,187 genes predicted to be targeted by these miRNAs were subjected to GO functional clustering. The results indicated that the major functional categories were &#x201c;protein binding&#x201d; (encompassing 414 genes, 54.83%), &#x201c;nucleus&#x201d; (261 genes, 34.57%), and &#x201c;transcription, DNA-templated&#x201d; (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>). This GO-based functional profiling elucidates the potential mechanistic roles of the SPHK2-regulated miRNA cohort, thereby furnishing a foundational resource for further mechanistic studies.</p>
<p>Our KEGG mapping implicated the significant enrichment of multiple signaling pathways, including &#x201c;Wnt signaling,&#x201d; &#x201c;p53 signaling,&#x201d; &#x201c;proteoglycans in cancer,&#x201d; and &#x201c;cell cycle&#x201d; (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>). Further analysis established the &#x201c;Wnt signaling pathway&#x201d; as the most significantly altered (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref>). Within this pathway, we observed the upregulation of 15 genes (i.e., <italic>SKP1</italic>, <italic>GSK3B</italic>, <italic>LRP6</italic>, <italic>BTRC</italic>, <italic>CCN4</italic>, <italic>INVS</italic>, <italic>SMAD4</italic>, <italic>SFRP1</italic>, <italic>NLK</italic>, <italic>FZD1</italic>, <italic>FZD2</italic>, <italic>FZD7</italic>, <italic>PRKACB</italic>, <italic>AXIN2</italic>, and <italic>PRICKLE2</italic>) and the downregulation of two genes (i.e., <italic>TBL1XR1</italic> and <italic>TP53</italic>), thereby pinpointing a specific set of candidate genes for future mechanistic studies.</p>
<p>The genes identified through KEGG analysis are compelling candidates that may play a role in macrophage polarization. For instance, <italic>GSK3B</italic> has been shown to phosphorylate and inactivate phosphatase and tensin homolog (PTEN), thereby potentiating the PI3K/Akt signaling pathway and promoting M2 polarization of the microglia (<xref ref-type="bibr" rid="B27">27</xref>). Similarly, regulatory T cells (Tregs) have been reported to alleviate inflammatory injury after intracerebral hemorrhage by shifting the microglia/macrophage polarization toward the M2 phenotype via the IL-10/<italic>GSK3B</italic>/PTEN axis (<xref ref-type="bibr" rid="B28">28</xref>). The expression of <italic>WISP1</italic> has also been linked to tumor purity and immune cell infiltration&#x2014;particularly monocyte&#x2013;macrophage trafficking and M2 polarization&#x2014;although its role appears context-dependent. In some cancers, a higher <italic>WISP1</italic> expression correlates with better prognosis and a reduced M2 macrophage infiltration (<xref ref-type="bibr" rid="B29">29</xref>). Furthermore, studies on Sfrp1-deficient murine macrophages treated with recombinant <italic>SFRP1</italic> revealed a decreased expression of the M2 marker Egr2 and an increased expression of the M1 marker Gpr18 (<xref ref-type="bibr" rid="B30">30</xref>). Based on this literature and our bioinformatics findings, we propose a hypothetical model: SPHK2 may promote TAM polarization toward the M2 phenotype by modulating the exosomal miRNA cargo, which in turn could influence the expression of key regulators such as <italic>GSK3B</italic>, <italic>WISP1</italic>, or <italic>SFRP1</italic>. This model provides a testable framework for future research. To determine which of these genes functionally contributes to M2 polarization, real-time PCR and Western blot analyses will be performed in subsequent studies.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, our study establishes that SPHK2 knockdown in glioma cells significantly reshapes the exosomal miRNA cargo, underscoring its role as a pivotal regulator of miRNA sorting and secretion. We delineated a subset of miRNAs (e.g., miR-195-5p) whose export is enhanced by SPHK2, as well as others (e.g., miR-4454 and miR-4516) whose export is suppressed. While the functional implications of these alterations require experimental validation, our KEGG analysis suggests a potential connection to the Wnt signaling pathway. Therefore, this work primarily forges a mechanistic link between SPHK2 and exosomal miRNA sorting, providing a foundational framework for future research to directly investigate the functional impact of these SPHK2-modified exosomes on recipient cells, such as macrophages.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.</p></sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>JL: Data curation, Conceptualization, Writing &#x2013; original draft. H-fZ: Methodology, Funding acquisition, Writing &#x2013; original draft. XL: Writing &#x2013; original draft, Formal Analysis. XG: Software, Writing &#x2013; original draft. QG: Software, Writing &#x2013; original draft. YX: Funding acquisition, Writing &#x2013; review &amp; editing. JQ: Writing &#x2013; review &amp; editing, Conceptualization.</p></sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors&#xa0;and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wesseling</surname> <given-names>P</given-names></name>
<name><surname>Capper</surname> <given-names>D</given-names></name>
</person-group>. 
<article-title>WHO 2016 classification of gliomas</article-title>. <source>Neuropathol Appl Neurobiol</source>. (<year>2018</year>) <volume>44</volume>:<page-range>139&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/nan.12432</pub-id>, PMID: <pub-id pub-id-type="pmid">28815663</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Capdevila</surname> <given-names>C</given-names></name>
<name><surname>Rodr&#xed;guez V&#xe1;zquez</surname> <given-names>L</given-names></name>
<name><surname>Mart&#xed;</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Glioblastoma multiforme and adult neurogenesis in the ventricular-subventricular zone: A review</article-title>. <source>J Cell Physiol</source>. (<year>2017</year>) <volume>232</volume>:<page-range>1596&#x2013;601</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcp.25502</pub-id>, PMID: <pub-id pub-id-type="pmid">27458813</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wirsching</surname> <given-names>HG</given-names></name>
<name><surname>Galanis</surname> <given-names>E</given-names></name>
<name><surname>Weller</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Glioblastoma</article-title>. <source>Handb Clin Neurol</source>. (<year>2016</year>) <volume>134</volume>:<page-range>381&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/B978-0-12-802997-8.00023-2</pub-id>, PMID: <pub-id pub-id-type="pmid">26948367</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dello Russo</surname> <given-names>C</given-names></name>
<name><surname>Lisi</surname> <given-names>L</given-names></name>
<name><surname>Tentori</surname> <given-names>L</given-names></name>
<name><surname>Navarra</surname> <given-names>P</given-names></name>
<name><surname>Graziani</surname> <given-names>G</given-names></name>
<name><surname>Combs</surname> <given-names>CK</given-names></name>
</person-group>. 
<article-title>Exploiting microglial functions for the treatment of glioblastoma</article-title>. <source>Curr Cancer Drug Targets</source>. (<year>2017</year>) <volume>17</volume>:<page-range>267&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1568009616666160813191240</pub-id>, PMID: <pub-id pub-id-type="pmid">27528361</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>JJ</given-names></name>
<name><surname>Lin</surname> <given-names>YC</given-names></name>
<name><surname>Yao</surname> <given-names>PL</given-names></name>
<name><surname>Yuan</surname> <given-names>A</given-names></name>
<name><surname>Chen</surname> <given-names>HY</given-names></name>
<name><surname>Shun</surname> <given-names>CT</given-names></name>
<etal/>
</person-group>. 
<article-title>Tumor-associated macrophages: the double-edged sword in cancer progression</article-title>. <source>JClin Oncol</source>. (<year>2005</year>) <volume>23</volume>:<page-range>953&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2005.12.172</pub-id>, PMID: <pub-id pub-id-type="pmid">15598976</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mantovani</surname> <given-names>A</given-names></name>
<name><surname>Ponzetta</surname> <given-names>A</given-names></name>
<name><surname>Inforzato</surname> <given-names>A</given-names></name>
<name><surname>Jaillon</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Innate immunity,inflammation and tumour progression: double-edged swords</article-title>. <source>J Intern Med</source>. (<year>2019</year>) <volume>285</volume>:<page-range>524&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/joim.12886</pub-id>, PMID: <pub-id pub-id-type="pmid">30873708</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Weigert</surname> <given-names>A</given-names></name>
<name><surname>von Knethen</surname> <given-names>A</given-names></name>
<name><surname>Thomas</surname> <given-names>D</given-names></name>
<name><surname>Faria</surname> <given-names>I</given-names></name>
<name><surname>Namgaladze</surname> <given-names>D</given-names></name>
<name><surname>Zezina</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation</article-title>. <source>Biochim Biophys Acta Mol Cell Biol Lipids</source>. (<year>2019</year>) <volume>1864</volume>:<page-range>1235&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbalip.2019.05.008</pub-id>, PMID: <pub-id pub-id-type="pmid">31128248</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ghosh</surname> <given-names>M</given-names></name>
<name><surname>Thangada</surname> <given-names>S</given-names></name>
<name><surname>Dasgupta</surname> <given-names>O</given-names></name>
<name><surname>Khanna</surname> <given-names>KM</given-names></name>
<name><surname>Yamase</surname> <given-names>HT</given-names></name>
<name><surname>Kashgarian</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction</article-title>. <source>PloS One</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e0194053</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0194053</pub-id>, PMID: <pub-id pub-id-type="pmid">29518138</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Weigert</surname> <given-names>A</given-names></name>
<name><surname>Schiffmann</surname> <given-names>S</given-names></name>
<name><surname>Sekar</surname> <given-names>D</given-names></name>
<name><surname>Ley</surname> <given-names>S</given-names></name>
<name><surname>Menrad</surname> <given-names>H</given-names></name>
<name><surname>Werno</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype</article-title>. <source>Int J Cancer</source>. (<year>2009</year>) <volume>125</volume>:<page-range>2114&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ijc.24594</pub-id>, PMID: <pub-id pub-id-type="pmid">19618460</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>J</given-names></name>
<name><surname>Zhou</surname> <given-names>Q</given-names></name>
<name><surname>Wu</surname> <given-names>CP</given-names></name>
<name><surname>Xu</surname> <given-names>YW</given-names></name>
<name><surname>Liu</surname> <given-names>WL</given-names></name>
<name><surname>Zhao</surname> <given-names>HF</given-names></name>
<etal/>
</person-group>. 
<article-title>SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma</article-title>. <source>Histol Histopathol</source>. (<year>2018</year>) <volume>33</volume>:<page-range>987&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.14670/HH-11-995</pub-id>, PMID: <pub-id pub-id-type="pmid">29697136</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>J</given-names></name>
<name><surname>Xu</surname> <given-names>Y</given-names></name>
<name><surname>Tang</surname> <given-names>H</given-names></name>
<name><surname>Liu</surname> <given-names>X</given-names></name>
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Wu</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>miR-137 is a diagnostic tumor-suppressive miRNA that targets SPHK2 to promote M1-type tumor-associated macrophage polarization</article-title>. <source>Exp Ther Med</source>. (<year>2023</year>) <volume>26</volume>:<fpage>397</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/etm.2023.12096</pub-id>, PMID: <pub-id pub-id-type="pmid">37533491</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seo</surname> <given-names>N</given-names></name>
<name><surname>Akiyoshi</surname> <given-names>K</given-names></name>
<name><surname>Shiku</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>Exosome-mediated regulation of tumor immunology</article-title>. <source>Cancer Sci</source>. (<year>2018</year>) <volume>109</volume>:<fpage>2998</fpage>&#x2013;<lpage>3004</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.13735</pub-id>, PMID: <pub-id pub-id-type="pmid">29999574</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Milane</surname> <given-names>L</given-names></name>
<name><surname>Singh</surname> <given-names>A</given-names></name>
<name><surname>Mattheolabakis</surname> <given-names>G</given-names></name>
<name><surname>Suresh</surname> <given-names>M</given-names></name>
<name><surname>Amiji</surname> <given-names>MM</given-names></name>
</person-group>. 
<article-title>Exosome mediated communication within the tumor microenvironment</article-title>. <source>J Control Release</source>. (<year>2015</year>) <volume>219</volume>:<page-range>278&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2015.06.029</pub-id>, PMID: <pub-id pub-id-type="pmid">26143224</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mohamed</surname> <given-names>NNI</given-names></name>
<name><surname>Okada</surname> <given-names>T</given-names></name>
<name><surname>Kajimoto</surname> <given-names>T</given-names></name>
<name><surname>Nakamura</surname> <given-names>SI</given-names></name>
</person-group>. 
<article-title>Essential role of sphingosine kinase 2 in the regulation of cargo contents in the exosomes from K562 cells</article-title>. <source>Kobe J Med Sci</source>. (<year>2018</year>) <volume>63</volume>:<page-range>E123&#x2013;9</page-range>., PMID: <pub-id pub-id-type="pmid">29955024</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Matarredona</surname> <given-names>ER</given-names></name>
<name><surname>Pastor</surname> <given-names>AM</given-names></name>
</person-group>. 
<article-title>Extracellular vesicle-mediated communication between the glioblastoma and its microenvironment</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>96</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells9010096</pub-id>, PMID: <pub-id pub-id-type="pmid">31906023</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saadatpour</surname> <given-names>L</given-names></name>
<name><surname>Fadaee</surname> <given-names>E</given-names></name>
<name><surname>Fadaei</surname> <given-names>S</given-names></name>
<name><surname>Nassiri Mansour</surname> <given-names>R</given-names></name>
<name><surname>Mohammadi</surname> <given-names>M</given-names></name>
<name><surname>Mousavi</surname> <given-names>SM</given-names></name>
<etal/>
</person-group>. 
<article-title>Glioblastoma: exosome and microRNA as novel diagnosis biomarkers</article-title>. <source>Cancer Gene Ther</source>. (<year>2016</year>) <volume>23</volume>:<page-range>415&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cgt.2016.48</pub-id>, PMID: <pub-id pub-id-type="pmid">27834360</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ashburner</surname> <given-names>M</given-names></name>
<name><surname>Ball</surname> <given-names>CA</given-names></name>
<name><surname>Blake</surname> <given-names>JA</given-names></name>
<name><surname>Botstein</surname> <given-names>D</given-names></name>
<name><surname>Butler</surname> <given-names>H</given-names></name>
<name><surname>Cherry</surname> <given-names>JM</given-names></name>
<etal/>
</person-group>. 
<article-title>Gene ontology: tool for the unification of biology</article-title>. <source>Gene Ontology Consortium. Nat Genet</source>. (<year>2000</year>) <volume>25</volume>:<page-range>25&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/75556</pub-id>, PMID: <pub-id pub-id-type="pmid">10802651</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Storey</surname> <given-names>JD</given-names></name>
</person-group>. 
<article-title>A direct approach to false discovery rates</article-title>. <source>J R Stat Society: Ser B (Statistical Methodology)</source>. (<year>2002</year>) <volume>64</volume>:<page-range>479&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/1467-9868.00346</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname> <given-names>Y</given-names></name>
<name><surname>Hochberg</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title>. <source>J R Stat Society. Ser B (Methodological)</source>. (<year>1995</year>) <volume>57</volume>:<fpage>289</fpage>&#x2013;<lpage>300</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2307/2346101</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kanehisa</surname> <given-names>M</given-names></name>
<name><surname>Goto</surname> <given-names>S</given-names></name>
<name><surname>Kawashima</surname> <given-names>S</given-names></name>
<name><surname>Okuno</surname> <given-names>Y</given-names></name>
<name><surname>Hattori</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>The KEGG resource for deciphering the genome</article-title>. <source>Nucleic Acids Res</source>. (<year>2004</year>) <volume>32</volume>:<page-range>D277&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkh063</pub-id>, PMID: <pub-id pub-id-type="pmid">14681412</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Van Brocklyn</surname> <given-names>JR</given-names></name>
<name><surname>Jackson</surname> <given-names>CA</given-names></name>
<name><surname>Pearl</surname> <given-names>DK</given-names></name>
<name><surname>Kotur</surname> <given-names>MS</given-names></name>
<name><surname>Snyder</surname> <given-names>PJ</given-names></name>
<name><surname>Prior</surname> <given-names>TW</given-names></name>
</person-group>. 
<article-title>Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2005</year>) <volume>64</volume>:<fpage>695</fpage>&#x2013;<lpage>705</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.jnen.0000175329.59092.2c</pub-id>, PMID: <pub-id pub-id-type="pmid">16106218</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname> <given-names>RJ</given-names></name>
<name><surname>Mathivanan</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Extracellular microvesicles: the need for internationally recognised nomenclature and stringent purification criteria</article-title>. <source>J&#xa0;Proteomics Bioinform</source>. (<year>2012</year>) <volume>5</volume>:<page-range>D1241&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkr828</pub-id>, PMID: <pub-id pub-id-type="pmid">21989406</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Montecalvo</surname> <given-names>A</given-names></name>
<name><surname>Larregina</surname> <given-names>AT</given-names></name>
<name><surname>Shufesky</surname> <given-names>WJ</given-names></name>
<name><surname>Stolz</surname> <given-names>DB</given-names></name>
<name><surname>Sullivan</surname> <given-names>ML</given-names></name>
<name><surname>Karlsson</surname> <given-names>JM</given-names></name>
<etal/>
</person-group>. 
<article-title>Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes</article-title>. <source>Blood</source>. (<year>2012</year>) <volume>119</volume>:<page-range>756&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2011-02-338004</pub-id>, PMID: <pub-id pub-id-type="pmid">22031862</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Momen-Heravi</surname> <given-names>F</given-names></name>
<name><surname>Balaj</surname> <given-names>L</given-names></name>
<name><surname>Alian</surname> <given-names>S</given-names></name>
<name><surname>Trachtenberg</surname> <given-names>AJ</given-names></name>
<name><surname>Hochberg</surname> <given-names>FH</given-names></name>
<name><surname>Skog</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Impact of biofluid viscosity on size and sedimentation efficiency of the isolated microvesicles</article-title>. <source>Front Physiol</source>. (<year>2012</year>) <volume>3</volume>:<elocation-id>162</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2012.00162</pub-id>, PMID: <pub-id pub-id-type="pmid">22661955</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lan</surname> <given-names>J</given-names></name>
<name><surname>Sun</surname> <given-names>L</given-names></name>
<name><surname>Xu</surname> <given-names>F</given-names></name>
<name><surname>Liu</surname> <given-names>L</given-names></name>
<name><surname>Hu</surname> <given-names>F</given-names></name>
<name><surname>Song</surname> <given-names>D</given-names></name>
<etal/>
</person-group>. 
<article-title>M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer</article-title>. <source>Cancer Res</source>. (<year>2019</year>) <volume>79</volume>:<page-range>146&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0014</pub-id>, PMID: <pub-id pub-id-type="pmid">30401711</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Su</surname> <given-names>MJ</given-names></name>
<name><surname>Aldawsari</surname> <given-names>H</given-names></name>
<name><surname>Amiji</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<elocation-id>30110</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep30110</pub-id>, PMID: <pub-id pub-id-type="pmid">27443190</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>G</given-names></name>
<name><surname>Shi</surname> <given-names>Y</given-names></name>
<name><surname>Jiang</surname> <given-names>X</given-names></name>
<name><surname>Leak</surname> <given-names>RK</given-names></name>
<name><surname>Hu</surname> <given-names>X</given-names></name>
<name><surname>Wu</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3&#x3b2;/PTEN/Akt axis</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2015</year>) <volume>112</volume>:<page-range>2853&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1501441112</pub-id>, PMID: <pub-id pub-id-type="pmid">25691750</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname> <given-names>K</given-names></name>
<name><surname>Zhong</surname> <given-names>Q</given-names></name>
<name><surname>Wang</surname> <given-names>YC</given-names></name>
<name><surname>Xiong</surname> <given-names>XY</given-names></name>
<name><surname>Meng</surname> <given-names>ZY</given-names></name>
<name><surname>Zhao</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Regulatory T cells ameliorate intracerebral hemorrhage-induced inflammatory injury by modulating microglia/macrophage polarization through the IL-10/GSK3&#x3b2;/PTEN axis</article-title>. <source>J Cereb Blood Flow Metab</source>. (<year>2017</year>) <volume>37</volume>:<page-range>967&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/0271678X16648712</pub-id>, PMID: <pub-id pub-id-type="pmid">27174997</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liao</surname> <given-names>X</given-names></name>
<name><surname>Bu</surname> <given-names>Y</given-names></name>
<name><surname>Xu</surname> <given-names>Z</given-names></name>
<name><surname>Jia</surname> <given-names>F</given-names></name>
<name><surname>Chang</surname> <given-names>F</given-names></name>
<name><surname>Liang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>WISP1 predicts clinical prognosis and is associated with tumor purity, immunocyte infiltration, and macrophage M2 polarization in pan-cancer</article-title>. <source>Front Genet</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>502</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2020.00502</pub-id>, PMID: <pub-id pub-id-type="pmid">32523603</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gregory</surname> <given-names>KJ</given-names></name>
<name><surname>Morin</surname> <given-names>SM</given-names></name>
<name><surname>Schneider</surname> <given-names>SS</given-names></name>
</person-group>. 
<article-title>Regulation of early growth response 2 expression by secreted frizzled related protein 1</article-title>. <source>BMC Cancer</source>. (<year>2017</year>) <volume>17</volume>:<fpage>473</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-017-3426-y</pub-id>, PMID: <pub-id pub-id-type="pmid">28687085</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/663589">Brian D. Adams</ext-link>, Brain Institute of America, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1282358">Haoyu Li</ext-link>, Central South University, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1761417">Jinxiang Wang</ext-link>, Sun Yat-sen University, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3266757">Jessica Oliveira de Santis</ext-link>, University of S&#xe3;o Paulo, Brazil</p></fn>
</fn-group>
</back>
</article>